N/A N=81 Health Services Research

Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy

Clinical Trials · Immunotherapy

Bottom Line

View on ClinicalTrials.gov: NCT05034289 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Acceptability of Intervention — 4.11 Score (1-5 scale)

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: PINPOINT Digital Educational Tool (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Rutgers, The State University of New Jersey
Primary completion: May 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Acceptability of Intervention	4.11	—
PRIMARY Appropriateness of Intervention	4.04	—
SECONDARY Knowledge About Precision Oncology	0.83; 1.20	0.052
SECONDARY Knowledge About Clinical Trials	2.07; 2.73	0.001 sig
SECONDARY Decision Self-efficacy for Tumor Genomic Sequencing.	78.11; 79.92	0.70
SECONDARY Decision Self-efficacy for Targeted/Immune Therapy	77.12; 87.35	0.0495 sig
SECONDARY Patient Empowerment	64.67; 68.4	0.31

Summary

The purpose of the research is to: develop an educational website to empower Black and African American cancer patients to make informed decisions about personalized cancer treatment and clinical trials. The sample size for the qualitative interviews was (n=48) when saturation was achieved. With a goal of (n=33) for the pilot trial, the overall target sample size for the study is (n=81).

Eligibility Criteria

Inclusion Criteria

Patient Key Informant:

Age 18 and older
Self-identify as Black/African American
Diagnosed with solid tumor
Able to read and speak English fluently
Able to provide informed consent
Able to complete 1 survey and an in-depth interview

Relative Key Informant:

Age 18 and older
Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American
Able to read and speak English fluently
Able to provide informed consent
Able to complete 1 survey and an in-depth interview

Provider Key Informant:

Age 18 and older
Physician, nurse, social worker, patient navigator, or financial counselor
Work in oncology setting
Able to read and speak English fluently
Able to provide informed consent
Able to complete 1 survey and an in-depth interview

Pilot Tester:

Age 18 and older
Self-identify as Black/African American
Able to read and speak English fluently
Able to provide informed consent
Newly diagnosed with solid tumor cancer (Stage I-IV)
Have not yet consulted with an oncologist regarding treatment
Able to complete 2 surveys and an in-depth interview

Exclusion Criteria

Key informants will be excluded from the study if they do not meet the inclusion criteria. Pilot testers will be excluded from the study if they previously participated as key informants and do not meet inclusion criteria.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05034289). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.